• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过氧化物酶体增殖物激活受体γ诱导人结肠癌细胞的生长停滞和分化标志物。

Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells.

作者信息

Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y

机构信息

Second Department of Internal Medicine, Osaka University Medical School.

出版信息

Jpn J Cancer Res. 1999 Jan;90(1):75-80. doi: 10.1111/j.1349-7006.1999.tb00668.x.

DOI:10.1111/j.1349-7006.1999.tb00668.x
PMID:10076568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5925976/
Abstract

Peroxisome proliferator-activated receptor gamma (PPAR gamma), one of the nuclear receptors expressed in adipose tissue, plays an important role in adipocyte differentiation. In this study, we investigated the expression of PPAR gamma and its role in cellular growth and differentiation in six colon cancer cell lines: HT-29, CaCo-2, SW-480, DLD-1, LoVo, and T-84. All six expressed PPAR gamma mRNA and protein, shown respectively on northern and western blot analyses. Luciferase assay in HT-29 cells, which strongly express PPAR gamma, showed that troglitazone, a selective ligand for PPAR gamma, transactivated the transcription of a peroxisome proliferator response element (PPRE)-driven promoter. Furthermore, troglitazone caused a marked decrease in [3H]thymidine incorporation and G1 cell-cycle arrest determined by flow cytometry. Finally, troglitazone induced expression of mRNAs for villin and intestinal alkaline phosphatase, markers for enterocyte differentiation. In conclusion, human colon cancer cells express PPAR gamma, the ligands of which inhibit cell growth and induce differentiation markers.

摘要

过氧化物酶体增殖物激活受体γ(PPARγ)是在脂肪组织中表达的核受体之一,在脂肪细胞分化中起重要作用。在本研究中,我们调查了PPARγ在六种结肠癌细胞系(HT-29、CaCo-2、SW-480、DLD-1、LoVo和T-84)中的表达及其在细胞生长和分化中的作用。通过Northern印迹和Western印迹分析分别显示,所有这六种细胞系均表达PPARγ mRNA和蛋白。在强烈表达PPARγ的HT-29细胞中进行的荧光素酶测定表明,PPARγ的选择性配体曲格列酮可反式激活过氧化物酶体增殖物反应元件(PPRE)驱动的启动子的转录。此外,曲格列酮导致[3H]胸苷掺入显著减少,并通过流式细胞术确定G1期细胞周期停滞。最后,曲格列酮诱导了绒毛蛋白和肠碱性磷酸酶的mRNA表达,这两种蛋白是肠上皮细胞分化的标志物。总之,人结肠癌细胞表达PPARγ,其配体可抑制细胞生长并诱导分化标志物。

相似文献

1
Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells.过氧化物酶体增殖物激活受体γ诱导人结肠癌细胞的生长停滞和分化标志物。
Jpn J Cancer Res. 1999 Jan;90(1):75-80. doi: 10.1111/j.1349-7006.1999.tb00668.x.
2
Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.曲格列酮激活过氧化物酶体增殖物激活受体γ通过增加人胰腺癌细胞中p27KiP1来抑制细胞生长。
Cancer Res. 2000 Oct 1;60(19):5558-64.
3
Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity.曲格列酮是一种过氧化物酶体增殖物激活受体γ(PPARγ)配体,可独立于PPARγ选择性诱导早期生长反应-1基因。这是其抗肿瘤活性的一种新机制。
J Biol Chem. 2003 Feb 21;278(8):5845-53. doi: 10.1074/jbc.M208394200. Epub 2002 Dec 9.
4
Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone.曲格列酮诱导结肠癌细胞系分化及过氧化物酶体增殖物激活受体γ表达
J Cancer Res Clin Oncol. 2004 Feb;130(2):73-9. doi: 10.1007/s00432-003-0510-2. Epub 2003 Nov 21.
5
Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-gamma ligands.过氧化物酶体增殖物激活受体γ配体对食管鳞状癌细胞的生长抑制作用
J Lab Clin Med. 2002 Jul;140(1):17-26. doi: 10.1067/mlc.2002.125055.
6
Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.过氧化物酶体增殖物激活受体γ对血管平滑肌细胞中生长停滞和DNA损伤诱导基因45(GADD45)的调控
Circ Res. 2003 Aug 22;93(4):e38-47. doi: 10.1161/01.RES.0000088344.15288.E6. Epub 2003 Jul 24.
7
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.过氧化物酶体增殖物激活受体γ(PPARγ)在人移行性膀胱癌中的表达及其在诱导细胞死亡中的作用。
Neoplasia. 1999 Oct;1(4):330-9. doi: 10.1038/sj.neo.7900050.
8
Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation.过氧化物酶体增殖物激活受体γ1(PPARγ1)在大鼠系膜细胞中表达,且PPARγ激动剂可调节其分化。
Biochim Biophys Acta. 2000 Jun 2;1497(1):148-54. doi: 10.1016/s0167-4889(00)00054-9.
9
Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.过氧化物酶体增殖物激活受体(PPAR)-γ在人血管平滑肌细胞中的表达:过氧化物酶体增殖物激活受体(PPAR)-γ激活剂曲格列酮对生长、迁移和c-fos表达的抑制作用
Am J Hypertens. 2000 Jan;13(1 Pt 1):74-82. doi: 10.1016/s0895-7061(99)00148-x.
10
PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity.过氧化物酶体增殖物激活受体γ(PPAR-γ)配体通过诱导细胞凋亡、细胞周期停滞以及降低鸟氨酸脱羧酶活性来抑制人食管腺癌细胞的生长。
Int J Oncol. 2001 Sep;19(3):465-71.

引用本文的文献

1
PPAR-γ in Melanoma and Immune Cells: Insights into Disease Pathogenesis and Therapeutic Implications.黑色素瘤与免疫细胞中的过氧化物酶体增殖物激活受体γ:对疾病发病机制及治疗意义的见解
Cells. 2025 Apr 2;14(7):534. doi: 10.3390/cells14070534.
2
Inhibition of the Wnt/β‑catenin signaling pathway and SOX9 by XAV939 did not alleviate inflammation in a dextran sulfate sodium‑induced ulcerative colitis model.XAV939对Wnt/β-连环蛋白信号通路和SOX9的抑制作用并不能减轻葡聚糖硫酸钠诱导的溃疡性结肠炎模型中的炎症。
Exp Ther Med. 2024 Nov 26;29(2):24. doi: 10.3892/etm.2024.12774. eCollection 2025 Feb.
3
Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology.噻唑烷二酮衍生物在癌症治疗中的应用:探索肿瘤学中的新机制、治疗潜力及未来前景
Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398(5):4705-4725. doi: 10.1007/s00210-024-03661-z. Epub 2024 Dec 2.
4
PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments.经过 35 年的全球科学研究和医学实验,PPARs 在临床实验医学中的应用。
Biomolecules. 2024 Jul 1;14(7):786. doi: 10.3390/biom14070786.
5
Use of drugs for hyperlipidaemia and diabetes and risk of primary and secondary brain tumours: nested case-control studies using the UK Clinical Practice Research Datalink (CPRD).药物治疗高脂血症和糖尿病与原发性和继发性脑肿瘤风险:使用英国临床实践研究数据库(CPRD)的巢式病例对照研究。
BMJ Open. 2024 Feb 9;14(2):e072026. doi: 10.1136/bmjopen-2023-072026.
6
Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.过氧化物酶体增殖物激活受体与癌症的特征。
Cells. 2022 Aug 5;11(15):2432. doi: 10.3390/cells11152432.
7
NSAIDs Induce Proline Dehydrogenase/Proline Oxidase-Dependent and Independent Apoptosis in MCF7 Breast Cancer Cells.非甾体抗炎药诱导MCF7乳腺癌细胞中脯氨酸脱氢酶/脯氨酸氧化酶依赖性和非依赖性凋亡。
Int J Mol Sci. 2022 Mar 30;23(7):3813. doi: 10.3390/ijms23073813.
8
Nonsteroidal Anti-Inflammatory Drugs as PPARγ Agonists Can Induce PRODH/POX-Dependent Apoptosis in Breast Cancer Cells: New Alternative Pathway in NSAID-Induced Apoptosis.非甾体抗炎药作为过氧化物酶体增殖物激活受体 γ 激动剂可诱导乳腺癌细胞中 PRODH/POX 依赖性细胞凋亡:非甾体抗炎药诱导细胞凋亡的新替代途径。
Int J Mol Sci. 2022 Jan 28;23(3):1510. doi: 10.3390/ijms23031510.
9
CB13, a novel PPARγ ligand, overcomes radio-resistance via ROS generation and ER stress in human non-small cell lung cancer.新型 PPARγ 配体 CB13 通过产生 ROS 和内质网应激克服人非小细胞肺癌的放射抵抗性。
Cell Death Dis. 2020 Oct 13;11(10):848. doi: 10.1038/s41419-020-03065-w.
10
A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor.一种新的非甾体抗炎药诱导癌细胞凋亡的合理机制:脯氨酸氧化酶和过氧化物酶体增殖物激活受体的作用。
Pharmacol Rep. 2020 Oct;72(5):1152-1160. doi: 10.1007/s43440-020-00140-z. Epub 2020 Jul 24.

本文引用的文献

1
Developmental adaptations of alkaline phosphatases in the small intestine.小肠中碱性磷酸酶的发育适应性
Fed Proc. 1962 Jan-Feb;21:51-6.
2
Terminal differentiation of human breast cancer through PPAR gamma.通过过氧化物酶体增殖物激活受体γ实现人乳腺癌的终末分化
Mol Cell. 1998 Feb;1(3):465-70. doi: 10.1016/s1097-2765(00)80047-7.
3
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.核类二十烷酸受体PPARγ在结肠癌中异常表达。
Carcinogenesis. 1998 Jan;19(1):49-53. doi: 10.1093/carcin/19.1.49.
4
Identification of an extended half-site motif required for the function of peroxisome proliferator-activated receptor alpha.过氧化物酶体增殖物激活受体α功能所需的扩展半位点基序的鉴定。
Genes Cells. 1997 May;2(5):315-27. doi: 10.1046/j.1365-2443.1997.1220319.x.
5
PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.过氧化物酶体增殖物激活受体γ诱导细胞周期停滞:通过下调蛋白磷酸酶2A抑制E2F/DP DNA结合活性。
Genes Dev. 1997 Aug 1;11(15):1987-98. doi: 10.1101/gad.11.15.1987.
6
Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients.过氧化物酶体增殖物激活受体和肝脏X受体-α的mRNA在人体中的组织分布及表达定量:肥胖和非胰岛素依赖型糖尿病患者脂肪组织无改变
Diabetes. 1997 Aug;46(8):1319-27. doi: 10.2337/diab.46.8.1319.
7
The organization, promoter analysis, and expression of the human PPARgamma gene.人类PPARγ基因的组织、启动子分析及表达
J Biol Chem. 1997 Jul 25;272(30):18779-89. doi: 10.1074/jbc.272.30.18779.
8
Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay.通过共激活因子依赖性受体配体测定法鉴定为过氧化物酶体增殖物激活受体配体的脂肪酸、类二十烷酸和降血脂药物。
Mol Endocrinol. 1997 Jun;11(6):779-91. doi: 10.1210/mend.11.6.0007.
9
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.脂肪酸和类二十烷酸通过与过氧化物酶体增殖物激活受体α和γ直接相互作用来调节基因表达。
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23. doi: 10.1073/pnas.94.9.4318.
10
Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists.人类过氧化物酶体增殖物激活受体(PPAR)亚型PPARγ2与PPARγ1的鉴定、特性及组织分布,以及视黄酸X受体激动剂和拮抗剂对其的激活作用
J Biol Chem. 1997 Mar 21;272(12):8071-6. doi: 10.1074/jbc.272.12.8071.